Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.

Neoplasma - 1 Jan 2010

Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J

Abstract excerpt

Breast cancer associated with BRCA1 and BRCA2 gene mutations differs from non-BRCA tumors in several respects. We determined whether there was any difference in CCND1 (11q13) and ZNF217 (20q13) gene amplification with respect to BRCA status. Of 40 breast cancer samples examined, 15 and 9 were from BRCA1 and BRCA2 mutation carriers, respectively, and 16 from patients without mutation. Fluorescence in situ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Mucinous
Share to Apoptosis Regulatory Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ductal, Breast

Share to Carcinoma, Lobular

Share to Cyclin D1

Share to Immunoenzyme Techniques

Share to Receptor, ErbB-2

Share to Receptors, Progesterone

Source

Identifiers

PMID: 20429623
DOI: 10.4149/neo_2010_04_325

Genes

CCND1
BRCA1
BRCA2
EGFR
ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.PMID 20429623Read ↗

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancersSemantic proximity Read ↗

Coexistence of copy number increases of c-Myc, ZNF217, CCND1, ErbB1 and ErbB2 in ovarian cancers.Semantic proximity Read ↗

ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunctionSemantic proximity Read ↗

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assaysSemantic proximity Read ↗

Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.Semantic proximity Read ↗

CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and PrognosisSemantic proximity Read ↗

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.Semantic proximity Read ↗

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.Semantic proximity Read ↗

Prognostic and therapeutic impact of the chromosome 20q13.2 <i>ZNF217</i> locus amplification in ovarian clear cell carcinomaSemantic proximity Read ↗

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.Semantic proximity Read ↗

Prognostic Relevance of Gene Amplifications and Coamplifications in Breast CancerSemantic proximity Read ↗

PPFIA1 and CCND1 are frequently coamplified in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.